3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasms
6
Anxiety Disorders
6
Head and Neck Neoplasms
3
Depression
3
Hot Flashes
2
Chronic Pain
2
Xerostomia
1
Vomiting
1
Uterine Cervical Neoplasms
1
Tendinopathy
1
Smoking Cessation
1
Sleep Wake Disorders
1
Radiculopathy
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pathophobia
1
Pain, Postoperative
1
Pain
1
Ovarian Neoplasms
1
Nociceptive Pain
1
Neuralgia, Postherpetic
1
Neuralgia
1
Nausea
1
Myocarditis
1
Musculoskeletal Pain
1
Melanoma
1
Medication Adherence
1
Lung Diseases, Interstitial
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
aldesleukin
134
Cyclophosphamide
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
67
dabrafenib
65
fludarabine phosphate
61
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
cobimetinib
32
Magnetic Resonance Spectroscopy
32
Introns
30
Specimen Handling
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
Hypnosis
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled